Articles

An open-label phase 2 trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928)

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN solid tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Bayesian randomized trial comparing intensity-modulated radiation therapy versus passively scattered proton therapy for locally advanced non–small-cell lung cancer

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

E1505: Adjuvant chemotherapy ± bevacizumab for early stage NSCLC—outcomes based on chemotherapy subsets

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC)

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

IFCT-1001 CHIVA trial: A phase II study of carboplatin (Ca) plus pemetrexed (P) followed by P maintenance, as first-line therapy for human immunodeficiency virus (HIV)-associated advanced non-squamous non-small-cell lung cancer (NS-NSCLC)

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Local consolidative therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (IST): Results of a multi-institutional phase II randomized study

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate-017/057 2-y update and exploratory cytokine profile analyses

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Open-label, multicenter, randomized phase III trial of pemetrexed/carboplatin doublet vs pemetrexed singlet in chemotherapy-naïve elderly patients aged 70 or more with advanced non-squamous non–small-cell lung cancer and good performance status

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Page 163 of 329